Faisal Khurshid
Stock Analyst at Leerink Partners
(4.55)
# 279
Out of 5,113 analysts
29
Total ratings
56.52%
Success rate
42.08%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $118 | $72.15 | +63.55% | 3 | Dec 9, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $10.96 | +45.99% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.99 | +0.25% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $34.64 | +15.47% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $14.09 | +41.94% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $83.12 | -12.17% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $4.02 | -50.25% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $105.53 | -3.35% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $5.14 | -80.54% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $33.36 | +34.89% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $19.41 | -17.57% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.27 | +57.48% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $0.71 | +2,163.08% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $80.45 | -0.56% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $6.43 | +133.28% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $18.67 | +141.03% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.38 | +407.25% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.59 | +43.11% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.62 | +703.60% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.86 | +284.62% | 1 | Mar 21, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $70 → $118
Current: $72.15
Upside: +63.55%
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $10.96
Upside: +45.99%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.99
Upside: +0.25%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $34.64
Upside: +15.47%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $14.09
Upside: +41.94%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $83.12
Upside: -12.17%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $4.02
Upside: -50.25%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $105.53
Upside: -3.35%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $5.14
Upside: -80.54%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $33.36
Upside: +34.89%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $19.41
Upside: -17.57%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.27
Upside: +57.48%
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.71
Upside: +2,163.08%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $80.45
Upside: -0.56%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $6.43
Upside: +133.28%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $18.67
Upside: +141.03%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.38
Upside: +407.25%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.59
Upside: +43.11%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.62
Upside: +703.60%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.86
Upside: +284.62%